Michael Skynner - 02 Jan 2026 Form 4 Insider Report for BICYCLE THERAPEUTICS PLC (BCYC)

Signature
/s/ Travis Thompson, Attorney-in-Fact
Issuer symbol
BCYC
Transactions as of
02 Jan 2026
Net transactions value
-$41,804
Form type
4
Filing time
06 Jan 2026, 20:00:38 UTC
Previous filing
06 Oct 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Skynner Michael CHIEF TECHNOLOGY OFFICER C/O BICYCLE THERAPEUTICS PLC, BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE, UNITED KINGDOM /s/ Travis Thompson, Attorney-in-Fact 06 Jan 2026 0001776582

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCYC Ordinary Shares Award $0 +50,000 +42% $0.000000 168,277 02 Jan 2026 Direct F1, F2
transaction BCYC Ordinary Shares Sale $20,706 -3,045 -1.8% $6.80 165,232 02 Jan 2026 Direct F3, F4
transaction BCYC Ordinary Shares Sale $21,098 -3,266 -2% $6.46 161,966 05 Jan 2026 Direct F3, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BCYC Employee Stock Option (right to buy) Award $0 +100,000 $0.000000 100,000 02 Jan 2026 Ordinary Shares 100,000 $7.08 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a restricted share unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2027 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter.
F2 Each RSU represents a contingent right to receive one ordinary share.
F3 Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.62 to $7.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) and (5).
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.30 to $6.70 inclusive.
F6 This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on January 2, 2027 and the remaining shares in 36 equal monthly installments thereafter.